Abstract Vascular endothelial growth factor (VEGF) is a key factor in angiogenesis and is important to carcinogenesis. Previous studies relating circulating levels of VEGF to breast cancer have been limited by small numbers of participants and lack of adjustment for confounders. We studied the association between serum VEGF and breast cancer in an unmatched case-control study of 407 pre-and postmenopausal women (n = 203 cases, n = 204 controls). Logistic regression was used to model the breast cancer risk as a function of natural log transformed VEGF levels adjusted for age, Gail score, education, physical activity, history of breastfeeding, serum testosterone, and hormone therapy (HT) use. The majority of the population was postmenopausal (67.6%) and the average age was 56 years; age and menopausal status were similar among cases and controls. Geometric mean VEGF levels were non-significantly higher in cases (321.4 pg/ml) than controls (291.4 pg/ml; p = 0.21). In a multivariable model, the odds of breast cancer was 37% higher for women with VEGF levels C314.2 pg/ml compared to those with levels below 314.2 pg/ml, albeit not significantly (p = 0.16).
Angiogenesis is the process of forming new blood vessels. Tumor growth is dependent on angiogenesis [6, 7] . Without vascularization, tumors are unable to grow beyond 1-2 mm 3 [8] . While angiogenesis is a multi-factorial, tightly controlled biological process, vascular endothelial growth factor (VEGF) is a primary promoter of angiogenesis [9] . VEGF is a potent mitogen with specificity for endothelial cells [9] and the ability to act on cancer cells [10] . VEGF has many functions, including promoting endothelial cell mitogenesis and survival, stromal degradation, and vascular permeability [10] . VEGF occurs in six different isoforms due to alternative splicing of the VEGF gene [11, 12] ; the 121 and 165 isoforms, which are secreted as soluble proteins, are the most abundant [11, 12] .
In vitro and animal studies provide strong evidence of an association between VEGF and breast cancer, though studies in humans are not definitive. Numerous studies have reported that plasma or serum VEGF levels are increased among women with breast cancer compared to those without [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] . These studies, however, are limited by small sample sizes, incomplete description of the study populations, and/or failure to control for potential confounders. Thus, the true association between VEGF levels and breast cancer remains unclear. Further, estrogen is known to be important in breast cancer development, and in vitro evidence indicates that estrogen may upregulate VEGF mRNA and protein expression [26] [27] [28] [29] [30] [31] . Few studies have investigated the associations between VEGF and estrogen in humans, however.
We conducted an unmatched case-control study of serum VEGF levels in relation to breast cancer in an ancillary study to the Mammograms and Masses Study (MAMS). Our primary hypothesis was that serum VEGF levels would be positively associated with breast cancer in this population of pre-and postmenopausal women. We also investigated associations between VEGF and direct and indirect measures of estrogen exposure.
Materials and methods

Study population
Mammograms and Masses Study is an unmatched casecontrol study of hormonal determinants of mammographic breast density [32] . Briefly, women were eligible for MAMS if they were of age C18 years and were receiving: (a) a breast biopsy, (b) an initial surgical consultation after breast cancer diagnosis, or (c) a routine screening mammogram. Exclusion criteria were prior cancer history other than non-melanoma skin cancer, alcohol intake [5 drinks per day, or weight \110 pounds or [300 pounds. Women were enrolled from 2001 to 2005 through mammography and surgical clinics operated by Magee-Womens Hospital, Pittsburgh, PA. Pathology reports were obtained for women recruited from biopsy and surgical clinics to ascertain their disease status (benign breast disease, in situ disease, or invasive cancer). Controls were recruited from women with negative findings on screening mammograms. Of the eligible respondents, 55% of cases and 55% of controls enrolled in MAMS. The MAMS study population consists of 1,133 women, including 264 cases with in situ or invasive breast cancer, 313 women with benign breast disease, and 556 controls.
A subset of MAMS participants was selected for this investigation of VEGF and breast cancer. We included only breast cancer cases and healthy controls; participants with benign breast disease were excluded (n = 313). Cases and controls were excluded from this analysis if they had no available mammogram (38 cases, 36 controls), were missing questionnaires (13 cases, 7 controls), had no available serum sample (5 cases, 5 controls), or if their blood draw was [14 days from enrollment (3 cases, 0 controls). After these exclusions 205 cases (66 premenopausal and 139 postmenopausal) and 508 controls (105 premenopausal and 403 postmenopausal) were eligible for the VEGF analysis. We included all 205 eligible cases and selected a simple random sample of 66 premenopausal and 139 postmenopausal controls from the 508 eligible controls. After completion of the VEGF analyses, three participants (1 control and 2 cases) were discovered to have a previous history of cancer and were excluded. The final 407 participants included 203 cases and 204 controls. The Institutional Review Board at the University of Pittsburgh approved this study, and all participants provided written informed consent.
Data collection
Participants completed a self-administered questionnaire that collected data on demographic characteristics, current and lifetime data on medical conditions and procedures, medications including HT and oral contraceptives (OCs), reproductive history, family cancer history, physical activity, smoking, and alcohol use. A research nurse measured participants' height and weight using a stadiometer and a standard balance beam scale while participants wore light clothing and no shoes.
Participants gave a non-fasting, 40 ml sample of peripheral blood at enrollment. The blood draw was not timed with the menstrual cycle for premenopausal women. Premenopausal women reported the date of their last menstrual period and the expected date of their next menstrual period, and menstrual cycle phase was inferred from this information. All blood samples were processed immediately at the Magee-Womens Hospital Satellite Clinical Research Center and stored at \-70°C.
Laboratory assays
Samples were relabeled with dummy identifiers and randomly distributed throughout the boxes transferred to the laboratories. A random sample of 40 masked duplicates (including 10 each from premenopausal cases and controls and postmenopausal cases and controls) was randomly distributed throughout the boxes for a reliability substudy. Samples were transferred, packed in dry ice. All laboratory staff were masked to the identity, disease status, and demographic and risk factor characteristics of the samples.
VEGF was measured in serum by enzyme-linked immunosorbent assay (Quantikine Ò Human VEGF Immunoassay, R&D Systems, Minneapolis, MN) [33] . This assay measures the 121 and 165 isoforms of VEGF-A and has a minimum detectable concentration of \5 pg/ml. The coefficient of variation (CV) for the VEGF assay was 14.2% (15.3% for pre-and 12.9% for postmenopausal women).
Estradiol (E2), follicle stimulating hormone (FSH), sex hormone binding globulin (SHBG), and testosterone (T) were measured in serum at the Clinical Ligand Assay Service Satellite (CLASS) Laboratory at the University of Michigan, School of Public Health. E2 was measured with a modified, off-line ACS:180 (E2-6) immunoassay (Bayer Diagnostics Corp, Tarrytown, NY) [34] . This assay has a detectable range of 1-250 pg/ml. FSH was measured with a two-site chemiluminescence (sandwich) immunoassay [35, 36] . This assay measures FSH concentrations from 0.3 to 200 mIU/ml. SHBG was measured using a competitive immunoassay run on Bayer Diagnostic's ACS:180 automated analyzer using chemiluminescent technology [35] . The detectable range for SHBG is 1.95-250 nM. Total T was measured using a modification of the ACS:180 total T assay to measure with greater precision samples in the low ranges found in women in postmenopause [37] . The limit of detection of this assay is \5.15 ng/dl. CVs were 42.3% for E2 (32.0% for pre-and 50.6% for postmenopausal women), 5.5% for FSH (6.1% for pre-and 4.8% for postmenopausal women), 14.6% for SHBG (11.5% for pre-and 17.2% for postmenopausal women), and 13.6% for T (15.6% for pre-and 11.3% for postmenopausal women). The high CV for E2 was related to the low concentrations of E2 observed in postmenopausal women; in the analyses, we categorized E2 into quartiles based on the control distribution because this provided more reliable data.
Statistical analysis
Descriptive statistics were calculated for participant characteristics and the laboratory measures. Biological measures below the detection limit for the assay were reset to the stated detection limit (n = 41 for E2, n = 4 for T). A natural log transformation was applied to all biological measures to improve normality. Distributions of variables were compared by disease status using two-sample t-tests for continuous variables and chi-square tests for categorical variables. We evaluated whether VEGF levels differed by recruitment site for controls using analysis of variance.
Variables associated with breast cancer or VEGF in previous studies were evaluated for their association with VEGF: age (continuous), race (White, other), educational level (high school, [high school), BMI (\25 kg/m 2 , 25 to \30 kg/m 2 , C30 kg/m 2 ), alcohol intake in year prior to enrollment (none, \12 g/d, C12 g/d), current alcohol use (no, yes), smoking status (never, former, current), cumulative physical activity in metabolic equivalent (MET)-hour/week (0, 0.1-10, C10.1), age at menarche (\13, C13), menstrual cycle regularity (no, yes, sometimes), menopausal status (premenopausal, postmenopausal without hysterectomy, postmenopausal with hysterectomy), age at menopause (premenopausal, \50, C50), menstrual cycle phase (luteal, follicular, unknown, postmenopausal), ever pregnant (no, yes), number of live births (none, 1, 2, C3), age at first pregnancy lasting [6 months (no live births/ pregnancy lasted \6 months, \20, 20-24, 25-29, C30), breastfeeding history (not applicable, no, yes), breast cancer family history (no, yes), cancer family history (no, yes), Gail score (\1.66%, C1.66%), previous breast biopsy (no, yes), diabetes (no, yes), myocardial infarction history (no, yes), heart disease history (no, yes), HT use (never, former, current), OC use (never, former, current), E2 (quartiles), FSH (quartiles), SHBG (quartiles), and T (quartiles). Categorizations of these variables were based on the common cutpoints (e.g. BMI) or on the original response categories with cells with small counts collapsed (e.g. age at menarche). Quartiles for E2, FSH, SHBG, and T were based on the distribution of these hormones among controls. VEGF was dichotomized based on the median level among the controls (\314.2 pg/ml, C314.2 pg/ml). Bivariate associations between dichotomous VEGF and these variables among control participants were assessed using chi-square tests or analysis of variance. Fisher's exact test was used in instances where the expected cell count was \5.
Logistic regression was used to evaluate the association between VEGF and breast cancer adjusting for relevant covariates. VEGF was modeled in separate regressions as a continuous, natural log transformed variable and as a dichotomous variable. Dummy variables were created for categorical variables as appropriate. The aforementioned variables were evaluated for inclusion as potential confounders, using backward selection based on likelihood ratio tests. All covariates with a p-value \0.10 from a likelihood ratio test were retained in the model. Fractional polynomials were used to assess the assumption that continuous variables were linear in the logit scale; these analyses indicated that this assumption was met for the continuous variables. The Hosmer-Lemeshow test was used to assess goodness of fit. Potentially influential observations were identified as those having significant influence on model deviance (as assessed by HosmerLemeshow's delta deviance test) or parameter estimates (as assessed by Pregibon's delta beta test). Likelihood ratio tests were used to evaluate the significance of hypothesized interactions by comparing the model including the interaction term to the main effects model.
All analyses were repeated among subgroups defined by menopausal status. Stata version 10.0 was used for all analyses (Stata Corporation, College Station, TX). Twosided p-values B0.05 were considered statistically significant, with no adjustment for multiple comparisons.
Results
The 407 participants comprising the study population are described in Table 1 . The mean age of both cases and controls was 56 (p = 0.99). The majority of the participants was non-Hispanic White, though participants of other ethnicities were somewhat more common among controls than cases (7.4% vs. 2.5%, p = 0.02). Compared to controls, cases exercised less (p \ 0.001), were less likely to have breastfed (p = 0.05), had a higher mean Gail score (p = 0.02), and were more likely to be current users of HT (p \ 0.001). Of the 203 cases, 52 (25.6%) had in situ disease and 151 (74.4%) had invasive cancer.
Distributions of VEGF and the measured reproductive hormones are summarized in Table 2 . The geometric mean of serum VEGF among cases (321.4 pg/ml) was nonsignificantly higher than that among controls (291.4 pg/ml, p = 0.21). There was no significant difference in the geometric mean of serum VEGF between in situ (328.6 pg/ml) and invasive cases (319.0 pg/ml; p = 0.81). We observed no significant difference in serum VEGF among controls by recruitment site (p = 0.32; data not shown). Similar VEGF levels were observed within the subgroups of preand postmenopausal women (data not shown). No significant differences were observed between cases and controls for the geometric means of E2 (15.5 vs. 12.6 pg/ml, p = 0.18), FSH (62.9 mIU/ml vs. 55.5 mIU/ml, p = 0.31), and SHBG (51.6 nM vs. 49.3 nM, p = 0.45). Geometric mean T levels were higher among cases (32.8 ng/dl) compared to controls (28.1 ng/dl; p = 0.01). When restricted to premenopausal women only, geometric mean FSH levels were significantly higher among cases (20.7 mIU/ml) than controls (13.4 mIU/ml; p = 0.05). Among postmenopausal women only, E2 levels were significantly higher among cases than controls (geometric mean 9.5 pg/ml vs. 6.8 pg/ml, respectively, p = 0.02; data not shown). Other hormone distributions were similar between these two subgroups.
Participants with high VEGF were more likely to have relatively high or relatively low levels of FSH (p = 0.04; Table 3 ). None of the other characteristics considered was significantly associated with serum VEGF levels among controls. Characteristics related to breast cancer risk, such as the Gail score, age at menopause, parity, and HT use, were similar among women with VEGF levels at or above the median level of controls (314.2 pg/ml) compared to those with lower levels. Results were similar in analyses restricted to premenopausal or postmenopausal women (data not shown).
In unadjusted and age-adjusted logistic regression analyses, associations between serum VEGF and breast cancer were not significant (Table 4 ). In a model adjusted for age, Gail score, education, physical activity, history of breastfeeding, serum T, and HT use, continuous VEGF was non-significantly positively associated with breast cancer (OR 1.21 per unit increase in ln(VEGF), 95% CI 0.91-1.59). Figure 1 illustrates this association by displaying odds ratios for specific levels of VEGF calculated from the continuous logistic regression model. For example, the odds of breast cancer were increased by 16% for a woman with a serum VEGF level of 691.4 pg/ml compared to a similar woman with a VEGF level of 291.4 pg/ml, albeit non-significantly.
In the comparable multivariable regression model with dichotomous VEGF, women with VEGF levels C314.2 pg/ml had a non-significant 37% increase in the odds of breast cancer (OR 1.37, 95% CI 0.88-2.12), compared to women with VEGF \314.2 pg/ml (Fig. 1) . Results were similar in a regression including cases with invasive cancer only (OR 1.41, 95% CI 0.88-2.27; p = 0.16). Further, results were attenuated but remained non-significant in a regression excluding six cases reporting tamoxifen use at enrollment (OR 1.17, 95% CI 0.89-1.55). The magnitude of the association between dichotomous VEGF and breast cancer was similar among premenopausal (OR 1.40, 95% CI 0.64-3.07) and postmenopausal women (OR 1.28, 95% CI 0.74-2.22). There was no indication of an interaction between VEGF and menopausal status (p = 0.52). Additionally, no significant interactions were observed between VEGF dichotomized at the control median and Gail score (p = 0.41), E2 (p = 0.62), or T (p = 0.88).
In exploratory analyses, we investigated whether HT use affected the association between VEGF and breast cancer ( Table 4 ). The logistic regression models were refit within subgroups defined by HT use (never, past, and current users). In multivariable models with dichotomous VEGF, no association between VEGF and breast cancer was observed among never HT users (OR 1.23, 95% CI 0.68-2.22) or We identified four influential observations (3 controls and 1 case) in the multivariable regression with dichotomous VEGF. In a sensitivity analysis excluding these four observations, the increase in breast cancer risk for women with VEGF greater than the median was similar to that observed in the full population and remained non-statistically significant (OR 1.45, 95% CI 0.92-2.27, p = 0.11).
Discussion
We found that increased serum VEGF levels were positively, but not significantly, associated with breast cancer in this case-control study. A woman with a serum VEGF level greater than the control median of 314.2 pg/ml, for example, had 37% higher odds of breast cancer compared to an otherwise similar woman with a serum VEGF level below 314.2 pg/ml (p = 0.16). Among premenopausal women, the strength of the association was somewhat greater (OR 1.40, 95% CI 0.64-3.07) than that among postmenopausal women (OR 1.28, 95% CI 0.74-2.22) though neither association achieved statistical significance. A formal test for interaction revealed that the association between VEGF and breast cancer was not significantly different between pre-and postmenopausal women (p = 0.52). Due to limited power to detect significance of such an interaction, future studies should examine whether the association between VEGF and breast cancer might be greater among premenopausal women.
The role of VEGF in angiogenesis and carcinogenesis is complex and likely involves interaction with multiple pathways. Of particular interest to breast cancer development is the possibility that hormones may regulate VEGF. Numerous in vitro studies report that estrogen increases VEGF mRNA and/or protein expression by breast cancer cells [26] [27] [28] [29] [30] [31] , although some do not support this finding [38, 39] . The selective estrogen receptor modulator tamoxifen may decrease VEGF expression [27, 28, 40] , though this finding is not consistent [30, 39] . Many studies report that progestin exposure increases VEGF expression [38, 41, 42] , though at least one found no effect [43] . Both natural and synthetic progestins are able to increase VEGF expression in vitro, and the synthetic progestin medroxyprogesterone acetate (MPA) is reported to have the strongest effect on VEGF expression [38, 41] . MPA is commonly used in postmenopausal HT, and it has been suggested that the strong effect of MPA on VEGF expression may at least partially explain the increased breast cancer risk observed in women using combination estrogen and progestin preparations versus those using estrogen alone [41] . Few human studies have investigated associations between hormones and VEGF in relation to breast cancer risk. A small study reported high correlations between VEGF in breast tissue and plasma E2 (r = 0.81, p \ 0.0001) and between VEGF and E2 both measured in breast tissue (r = 0.67, p = 0.004) [44] . We observed no significant association between serum VEGF and serum E2 among healthy controls, though women with VEGF levels C314.2 pg/ml were somewhat more likely to be in the lowest quartile of E2. Differences in the study populations and in the medium in which VEGF and E2 were measured preclude a direct comparison between these studies and may explain the discrepant results. We also observed a stronger, positive association between VEGF and breast cancer among past HT users. This association was not apparent among the small number of current HT users, and a formal test for an interaction between VEGF and HT use was not significant. Though exploratory, our results provide little evidence that steroid hormones are associated with VEGF. Our results are in contrast to previous reports finding positive and statistically significant associations between serum or plasma VEGF and breast cancer [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] 45] . For example, Heer et al. [20] reported that in a sample of 196 incident breast cancer cases and 88 healthy controls, the median serum VEGF level was higher in cases (305.9 pg/ml) than in controls (167.5 pg/ml; p \ 0.0005). Though our results agree with prior reports in terms of the direction of the association, we did not find such associations to be statistically significant. These previous studies, however, only performed comparisons of mean or median VEGF levels between cases and controls, and did not examine associations between VEGF and breast cancer in a multivariable context as we have done. The set of dark, solid bars on the left display odds ratios calculated for 200 pg/ml increments of serum VEGF relative to the control population geometric mean value of 291.4 pg/ml. The two lighter, hatched bars on the right display odds ratios for serum VEGF when dichotomized at the control population median of 314.2 pg/ml Further, there are important differences in our study population as compared to previous reports. Previous studies all included fewer than 100 healthy female controls, and most failed to describe how such controls were selected [13, 14, [18] [19] [20] 24] . Control participants in MAMS were recruited from healthy women seeking a screening mammogram. Our study population consisted of pre-and postmenopausal women ranging in age from 35 to 84. Many previous studies have failed to adequately describe the age [13, 16, 20, [22] [23] [24] [25] or menopausal status [13-17, 19-21, 23-25, 45, 46] of their study populations, making a direct comparison to the results observed in our wellcharacterized population difficult. The control VEGF distribution in our population differed substantially from previous reports. The arithmetic mean serum VEGF among controls was 387.5 pg/ml in our population, but ranged from 77.0 pg/ml to 230.0 pg/ml in other studies [13, 14, 23, 24] . Similarly, the median serum VEGF among our controls was 314.2 pg/ml compared to medians ranging from 17.0 pg/ml to 261.1 pg/ml reported in other studies [17] [18] [19] [20] [21] 47] . This may reflect the higher sensitivity of the assay used here, the influence of a selection bias within our study, or may indicate that serum VEGF levels among healthy women are higher and more variable than previously thought.
An important limitation to our study is the low statistical power. Although we estimated a priori that we would have greater than 80% power to detect a difference of 60 pg/ml in mean serum VEGF between cases and controls, the variability of VEGF in our study population far exceeded that observed in the study used as a basis for power calculations [13] . In fact, a posteriori power calculations showed that we had only 24% power to detect a difference between the mean values of serum VEGF we observed among cases and controls, which limited our ability to detect true differences in VEGF these groups.
The measurement of VEGF in serum rather than plasma may also limit our study. It has been demonstrated that platelets release VEGF into serum during routine specimen processing [13, [47] [48] [49] [50] [51] and that serum VEGF levels are highly correlated with the platelet count [18, 52] . For these reasons, many investigators have stated that plasma is the preferred specimen for measuring circulating VEGF [49] [50] [51] . Serum and plasma VEGF levels have been found to correlate significantly with one another in some studies [18, 53] , however, and some investigators still regard serum as the appropriate specimen for circulating VEGF measurements [54] . In our study, blood samples were processed identically for both cases and controls, so any effects of time between collection and processing or of our handling and storage methods which might affect release of VEGF from platelets into the serum should have affected cases and controls equally. We found that VEGF levels among controls did not vary by recruitment site, though it might be reasonable to suspect that specimen handling procedures may have differed slightly by recruitment site. Additionally, a study by McDowell et al. demonstrated that samples from women with early breast cancer and from healthy female controls showed no difference in the amount of VEGF released into the serum per platelet [55] , lending credibility to our results. Further, platelets have been demonstrated to be important to tumor growth, angiogenesis, and metastasis [54, 56] . Thus, the VEGF released from platelets into serum might reflect bioavailable VEGF which could impact tumor development. Though it is possible that serum may not be the optimal specimen for measurement of circulating VEGF, serum VEGF does appear to be relevant to tumor biology.
The relevance of circulating VEGF to tumor VEGF has also been questioned. Some studies have reported no correlation between serum VEGF and VEGF in tumor tissue [19, 50, 57] . Others have suggested, however, that measuring extracellular tumor levels of VEGF is more relevant than measuring tissue levels due to posttranslational activation of VEGF [44] . In fact, one study did report a weak but positive correlation between serum VEGF and VEGF in breast tumor cytosols (r = 0.32, p \ 0.05) but no correlation between serum VEGF and VEGF in the tumor tissue (r = 0.12, p [ 0.05) [58] . The relationship between circulating and tumor VEGF warrants further investigation.
Other limitations include the case-control design, which precludes temporal inferences. However, case-control studies are an important step towards recommending prospective studies. VEGF levels were assessed at a single point in time. The observed levels may not be representative of a participant's usual levels and could reflect recent changes in general health or medication use. The extensive data collected in MAMS allowed for statistical control of these variables and reduced potential confounding. Only a small percentage of MAMS participants were non-White, so our results may not apply to women of other races or ethnicities. Further, MAMS participants were better educated and less likely to smoke as compared to women from Allegheny County overall [32, 59] , indicating a possible volunteer bias.
Our results show that circulating VEGF may not distinguish breast cancer cases from controls. These results should be confirmed with additional epidemiological studies with control for confounders. Although we found no statistically significant differences in VEGF levels between breast cancer cases and controls, we did find that levels were higher among cases. VEGF has demonstrated importance in breast cancer development and in prognosis. Thus, it remains important to investigate whether VEGF levels measured prospectively predict subsequent breast cancer development.
